Neumora, enGene cut staff in cost-saving initiatives
Neuroscience biotech Neumora and genetic medicines company enGene both announce workforce reductions as part of cost-saving initiatives amid a broader sector pullback.
Neumora Therapeutics
Neumora Therapeutics is a clinical-stage neuroscience company developing precision medicines for brain diseases with high unmet need. Its lead asset NMRA-140 (navacaprant) is a kappa opioid receptor antagonist studied in major depressive disorder, and the company has additional programs in schizophrenia and other CNS indications. Following two Phase 3 failures in mid-2026, Neumora announced a 35% workforce reduction and is discontinuing development of its lead depression asset.
Company Info
Sector:Biotechnology / Neuroscience (Precision Psychiatry)
Headquarters:Watertown, Massachusetts, USA
Founded:2019
Website:neumoratx.com/
Upcoming Milestones & Key Dates
Q3 2026
Corporate
Completion of 35% workforce reduction and pipeline restructuring
Late 2026
Corporate
Strategic review of remaining pipeline and cash runway guidance
Clinical Development Pipeline
NMRA-140 (navacaprant)
Target: Kappa opioid receptor (KOR) antagonistNMRA-140 (navacaprant)
Target: Kappa opioid receptor (KOR) antagonistPreclinical KOR / DOR programs
Target: Opioid receptor modulatorsWorkforce & Restructuring Tracker
View Industry Layoff Tracker →35% of workforceConfirmed
Neumora Therapeutics laid off 35% of its staff and discontinued development of its lead kappa opioid receptor antagonist navacaprant (NMRA-140) in major depressive disorder following a pair of Phase 3 clinical trial misses.
Recent News
Neumora Discards Depression Asset, Lays Off Staffers After Pair of Late-Stage Flops
Neumora Therapeutics is laying off 35% of its workforce and discontinuing its lead depression drug after the asset failed two Phase 3 trials, sending shares down sharply and forcing a major pipeline reset.
Neumora discards depression asset, lays off staffers after pair of late-stage flops
Neumora discards depression asset, lays off staffers after pair of late-stage flops.
Leadership Team
Paul L. Berns
Chairman and Chief Executive Officer (since February 14, 2025)